Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A congenital myasthenic syndrome characterized by autosomal recessive inheritance of postsynaptic neuromuscular junction defects, early-onset progressive muscle weakness, and kinetic abnormalities of the AChR channel that has material basis in homozygous or compound heterozygous mutation in the CHRNE gene on chromosome 17p13.
Features include always present findings: Weakness of facial musculature, Ophthalmoplegia, Fatigable weakness of skeletal muscles, and EMG: decremental response of compound muscle action potential to repetitive nerve stimulation. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 7 | Low muscle tone (hypotonia), Weakness of facial musculature, Fatigable weakness of skeletal muscles |
CHRNE encodes cholinergic receptor nicotinic epsilon subunit (493 aa). After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane Highest expression in Heart Atrial Appendage (78.3 TPM) and Pituitary (74.9 TPM).
Congenital myasthenic syndrome 4B is associated with mutations in the CHRNE gene on chromosome 17.
CHRNE is classified as a druggable target (Druggable Genome, Ion Channel, and Transporter categories) with score 0.5.
Genetic testing for CHRNE is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for congenital myasthenic syndrome 4B has been reported in the published literature.
Phenotype severity distribution: 4 always present features.
No clinical trials have been registered for congenital myasthenic syndrome 4B.
3 publications have been identified in PubMed for congenital myasthenic syndrome 4B. Research spans Diagnostic / Biomarker (33%), Basic Science / Preclinical (33%), and Epidemiology / Natural History (33%).
Mroczek M (2026). [PMID: 41575592](https://pubmed.ncbi.nlm.nih.gov/41575592/). *J Neurol*. [Basic Science / Preclinical]
Ryan-Phillips F (2024). [PMID: 39595115](https://pubmed.ncbi.nlm.nih.gov/39595115/). *Biomedicines*. [Diagnostic / Biomarker]
Theuriet J (2024). [PMID: 38696726](https://pubmed.ncbi.nlm.nih.gov/38696726/). *Brain*. [Epidemiology / Natural History]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:01 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Digestive system | 1 | Feeding difficulties |
Lungs and breathing | 1 | Difficulty breathing (respiratory insufficiency) |
Head and neck | 1 | Weakness of facial musculature |
Lab test results | 1 | Anti-neuromuscular Junction acetylcholine receptor antibody positivity |
Eyes | 1 | Ptosis |
Bones and joints | 1 | Fatigable weakness of skeletal muscles |
Pregnancy and birth | 1 | Neonatal hypotonia |
Age of onset: newborn period.